Tom Bumol's career spans major roles at Eli Lilly, the Allen Institute, and beyond. He is also a distinguished member of CytoReason's Science Advisory Board.In this episode, Tom shares insights into drug development's successes, failures, and future direction, including:

• Lessons from lupus - the story of a failed lupus trial that revealed the critical importance of understanding disease heterogeneity and inspired new approaches in immunology.
• From trial and error to predictability - how AI and systems biology can transform drug development by embracing human complexity.
• Combination therapies and beyond - designing drugs with precision to improve patient outcomes and broaden therapeutic reach.

All this and much more in a captivating discussion with our Chief Scientist Shai Shen-Orr. Enjoy!